CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
The article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that...
Main Authors: | Ye. I. Alekseeva, R. V. Denisova |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2014-12-01
|
Series: | Voprosy Sovremennoj Pediatrii |
Subjects: | |
Online Access: | https://vsp.spr-journal.ru/jour/article/view/95 |
Similar Items
-
EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014-05-01) -
The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01) -
CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-09-01) -
Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
by: Abdulkadir A. Elmi, et al.
Published: (2019-07-01) -
CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014-03-01)